| Evolent Health, Inc. (EVH) Q1 2025 Earnings Call Transcript |
Evolent Health, Inc. (NYSE:EVH ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Jack Doney - UBS Matthew Gillmor - KeyBanc Ryan Daniels - William Blair Jessica Tassan - Piper Sandler Jeff Garro - Stephens Kyle Aikman - JPMorgan Matthew Shea - Needham Constantine Davides - Citizens Charles Rhyee - TD Cowen Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earning Conference Call for the First Quarter Ended March 31, 2025. As a reminder, this conference call is being recorded. |
seekingalpha.com |
2025-05-09 22:03:37 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Reports Q1 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Evolent Health (EVH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-09 19:01:07 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Q1 Earnings Lag Estimates |
Evolent Health (EVH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.34 per share a year ago. |
zacks.com |
2025-05-08 23:35:30 |
Czytaj oryginał (ang.) |
| Evolent Announces First Quarter 2025 Results |
WASHINGTON , May 8, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent Health kicked off 2025 with first quarter results at the high end of our expectations, and we are reiterating our outlook for full year 2025 revenue and Adjusted EBITDA. |
prnewswire.com |
2025-05-08 20:10:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Evolent Health (EVH) Could Rally 53.33%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-05-07 15:00:59 |
Czytaj oryginał (ang.) |
| Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors |
Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts. |
prnewswire.com |
2025-04-22 10:30:00 |
Czytaj oryginał (ang.) |
| Evolent program achieves 20% reduction in use of low-value oncology regimens |
Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens. |
prnewswire.com |
2025-04-15 13:00:00 |
Czytaj oryginał (ang.) |
| Evolent To Release First Quarter 2025 Financial Results on Thursday, May 8, 2025 |
Company to Participate in Upcoming Conferences WASHINGTON , April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. |
prnewswire.com |
2025-04-10 21:00:00 |
Czytaj oryginał (ang.) |
| Evolent Health, Inc. (EVH) Q4 2024 Earnings Call Transcript |
Evolent Health, Inc. (NYSE:EVH ) Q4 2024 Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Matthew Gillmor - KeyBanc Charles Rhyee - TD Cowen Andrea Alfonso - UBS Jailendra Singh - Truist Securities Ryan Daniels - William Blair Jeff Garro – Stephens Anne Samuel - J.P. Morgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler David Larsen - BTIG Daniel Grosslight – Citi Matthew Shea - Needham Operator Welcome to the Evolent Earnings Conference Call for the Fourth Quarter and Year End December 31, 2024. |
seekingalpha.com |
2025-02-20 21:28:10 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-20 21:01:31 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Reports Q4 Loss, Lags Revenue Estimates |
Evolent Health (EVH) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.23 per share a year ago. |
zacks.com |
2025-02-20 20:40:29 |
Czytaj oryginał (ang.) |
| Evolent Announces Fourth Quarter and Full Year 2024 Results |
Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively. Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively. |
prnewswire.com |
2025-02-20 18:10:00 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:27 |
Czytaj oryginał (ang.) |
| Earnings Preview: Evolent Health (EVH) Q4 Earnings Expected to Decline |
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-13 13:07:04 |
Czytaj oryginał (ang.) |
| Evolent Health Announces Changes to Board of Directors |
Richard " Rick " Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb ' s Appointment as New Independent Director WASHINGTON , Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott. |
prnewswire.com |
2025-02-04 09:00:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for January 30th |
DEC, ERO and EVH have been added to the Zacks Rank #5 (Strong Sell) List on January 30, 2024. |
zacks.com |
2025-01-30 06:06:15 |
Czytaj oryginał (ang.) |
| Evolent To Release Fourth Quarter 2024 Financial Results on Thursday, February 20, 2025 |
Company to Participate in Upcoming Conferences WASHINGTON , Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. |
prnewswire.com |
2025-01-27 19:00:00 |
Czytaj oryginał (ang.) |
| Evolent dips after Truist warns guidance may be 'significantly' below consensus |
Truist analyst Jailendra Singh caught up with Evolent Health post its presentation at an investor healthcare conference and also noted that the company released an 8-K earlier in the week outlining some preliminary views on 2025. Evolent is encouraging investors to use Q4 EBITDA run-rate as the baseline for 2025 and the firm now sees the company's 2025 guidance range coming in "significantly below consensus," the analyst tells investors. Using about $25M of Q4 EBITDA as a baseline, the firm infers that Evolent is suggesting a potential initial FY25 EBITDA range of $140M-$170M, said the analyst, who has a Buy rating and $20 price target on the shares. In Wednesday trading, Evolent shares slid 10% to $10.02. |
https://thefly.com |
2025-01-15 17:59:22 |
Czytaj oryginał (ang.) |
| Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1 |
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON , Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. |
prnewswire.com |
2024-12-18 18:10:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for December 12th |
ASH, BIDU and EVH have been added to the Zacks Rank #5 (Strong Sell) List on December 12, 2024. |
zacks.com |
2024-12-12 07:16:08 |
Czytaj oryginał (ang.) |
| Evolent Health: A Shot At Revival After Market Bruising |
Evolent Health has seen a significant 50% drop due to a Q3 earnings miss and high medical costs. Despite setbacks, Evolent secured record-breaking new business deals and anticipates over 15% annual revenue growth, driven by rate increases and strategic partnerships. EVH stock appears undervalued with a P/E ratio of 16.57, suggesting a potential contrarian buy opportunity given its long-term growth prospects. |
seekingalpha.com |
2024-11-12 04:37:44 |
Czytaj oryginał (ang.) |
| Evolent Health, Inc. (EVH) Q3 2024 Earnings Call Transcript |
Evolent Health, Inc. (NYSE:EVH ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Participants Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Seth Frank - Vice President, Investor Relations Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Jeff Garro - Stephens Stephanie Davis - Barclays Ryan Daniels - William Blair Matthew Gillmor - KeyBanc Kyle Aikman - J.P. Morgan Richard Close - Canaccord Genuity Sean Dodge - RBC Capital Markets Jessica Tassan - Piper Sandler Kevin Caliendo - UBS Daniel Grosslight - Citi David Larsen - BTIG Operator Welcome to the Evolent Earnings Conference Call for the Third Quarter Ended September 30, 2024. |
seekingalpha.com |
2024-11-09 11:12:10 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics |
The headline numbers for Evolent Health (EVH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-08 18:30:17 |
Czytaj oryginał (ang.) |
| Sweetgreen Posts Downbeat Results, Joins Evolent Health, Redfin, Pinterest And Other Big Stocks Moving Lower In Friday's Pre-Market Session |
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.2% on Friday. |
benzinga.com |
2024-11-08 10:47:42 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Q3 Earnings and Revenues Lag Estimates |
Evolent Health (EVH) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.30 per share a year ago. |
zacks.com |
2024-11-07 21:00:47 |
Czytaj oryginał (ang.) |
| Evolent Announces Third Quarter 2024 Results |
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%. |
prnewswire.com |
2024-11-07 18:10:00 |
Czytaj oryginał (ang.) |
| Unlocking Q3 Potential of Evolent Health (EVH): Exploring Wall Street Estimates for Key Metrics |
Beyond analysts' top -and-bottom-line estimates for Evolent Health (EVH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024. |
zacks.com |
2024-11-06 12:20:24 |
Czytaj oryginał (ang.) |
| Why Evolent Health (EVH) is Poised to Beat Earnings Estimates Again |
Evolent Health (EVH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2024-11-05 15:11:09 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Reports Next Week: What to Know Ahead of the Release |
Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:06:59 |
Czytaj oryginał (ang.) |
| Evolent To Release Third Quarter 2024 Financial Results on Thursday, November 7, 2024 |
Company to Participate in Upcoming Conferences WASHINGTON , Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. |
prnewswire.com |
2024-10-11 12:00:00 |
Czytaj oryginał (ang.) |
| Evolent Health Inc (EVH) Stock Price Down 3.2% on Oct 2 |
Shares of Evolent Health Inc (EVH, Financial) fell 3.20% in mid-day trading on Oct 2. The stock reached an intraday low of $25.76, before recovering slightly to $26.19, down from its previous close of $27.05. |
gurufocus.com |
2024-10-02 16:08:07 |
Czytaj oryginał (ang.) |
| Evolent Health: Let The Bidding Begin |
Evolent Health is potentially being taken private at a bid of $3.8 billion, offering a 15% upside to the stock at $32 per share. The company's revenue growth rates are expected to decelerate, but potential bidding wars may drive up the stock price further. Evolent's current valuation at 21x forward free cash flow may undervalue the company, potentially leading to higher bids in the future. |
seekingalpha.com |
2024-08-23 13:00:00 |
Czytaj oryginał (ang.) |
| Exclusive: Evolent Health in sale talks after inbound interest, sources say |
Evolent Health is in talks with private equity firms and other companies for a potential sale, in a process that kicked off after the healthcare services provider received inbound interest, people familiar with the matter said on Thursday. |
reuters.com |
2024-08-22 17:22:17 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Reports Q2 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-08-09 14:30:46 |
Czytaj oryginał (ang.) |
| Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript |
Evolent Health, Inc. (EVH) Q2 2024 Earnings Call Transcript |
seekingalpha.com |
2024-08-09 01:18:06 |
Czytaj oryginał (ang.) |
| Evolent Health (EVH) Surpasses Q2 Earnings and Revenue Estimates |
Evolent Health (EVH) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.14 per share a year ago. |
zacks.com |
2024-08-08 22:31:13 |
Czytaj oryginał (ang.) |
| Evolent Announces Second Quarter 2024 Results |
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%. |
prnewswire.com |
2024-08-08 20:10:00 |
Czytaj oryginał (ang.) |
| 3 Top Tech Stocks Ready for Robust Gains |
Investors must always balance growth and stability in their portfolios. While employing defensive positions is essential, deploying capital in high-growth sectors like technology can be a formula that accelerates growth. |
investorplace.com |
2024-08-04 10:46:00 |
Czytaj oryginał (ang.) |